title: Decrease of angiotensin-converting enzyme activity after plasma exchange.
abstract: We measured sequential changes in serum angiotensin-converting enzyme (ACE) in 12 ICU patients undergoing plasma exchange (PE) with plasma substitutes (albumin-Polygelin). A dramatic decrease in serum ACE activity was observed after each of the 51 PE procedures. Repeated PE procedures resulted in almost a total depletion of serum ACE, which returned to normal ranges in 4 to 10 days. No ACE change was observed during hemodialysis or hemofiltration. ACE activity increased after PE with fresh frozen plasma replacement. ACE changes were compared with IgG, antithrombin III, and fibronectin changes. Extraction ratio comparisons were consistent, with a loss in removed plasma accounting for 50% to 70% of the observed ACE decrease. Plasma zinc levels were not modified after PE. Mixing experiments with increasing volumes of plasma substitutes showed ACE inhibition by Polygelin. In vivo infusion of Polygelin had the same effect. The renin-induced aldosterone response studied in six exchanged patients was consistent with a relative hyperreninemic hypoaldosteronism after repeated PE. These findings may be of clinical relevance during acute hypovolemia and dehydration after PE or Polygelin infusion and in patients with impaired lung endothelial function.
authors.affiliation: Service de Réanimation Polyvalente, Hôpital B. Lille, France.
authors.forename: F
authors.initials: F
authors.lastname: Fourrier
authors.forename: L
authors.initials: L
authors.lastname: Leclerc
authors.forename: P
authors.initials: P
authors.lastname: Lestavel
authors.forename: A
authors.initials: A
authors.lastname: Racadot
authors.forename: M C
authors.initials: MC
authors.lastname: Chambrin
authors.forename: J
authors.initials: J
authors.lastname: Mangalaboyi
authors.forename: C
authors.initials: C
authors.lastname: Chopin
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D005353:Fibronectins / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000628:therapy; D007703:Peptidyl-Dipeptidase A / Q000097:blood*; D010951:Plasma Exchange / Q000009:adverse effects; D011097:Polygeline / Q000009:adverse effects / Q000494:pharmacology*; D011108:Polymers / Q000494:pharmacology*; D011129:Polyradiculoneuropathy / Q000628:therapy; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D005353:Fibronectins; D007074:Immunoglobulin G; D011108:Polymers; D000990:Antithrombin III; D011097:Polygeline; D007703:Peptidyl-Dipeptidase A